Clarity is a high-risk, high-upside radiotheranostics challenger whose copper-based platform could disrupt prostate cancer imaging and therapy if Phase III approvals arrive on schedule.
Overview
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing Targeted Copper Theranostics using copper-64 for PET imaging and copper-67 for therapy. Its SAR platform aims to deliver higher-precision cancer detection and treatment, especially in prostate cancer and neuroendocrine tumors. The company has no commercial product revenue today and relies on equity funding and R&D incentives, but its diagnostic-first commercialization plan could generate early high-margin revenue to fund therapeutic trials. Clinical data suggests superior lesion detection and supply-chain reliability versus current radiopharmaceutical standards.